APA (7th ed.) Citation

Kasper, B., Frühauf, S., Schiedlmeier, B., Buchdunger, E., Ho, A. D., & Zeller, W. J. (1999). Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor: Activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer chemotherapy and pharmacology, 44(5), . https://doi.org/10.1007/s002800051001

Chicago Style (17th ed.) Citation

Kasper, Bernd, Stefan Frühauf, Bernd Schiedlmeier, Elisabeth Buchdunger, Anthony Dick Ho, and W. Jens Zeller. "Favorable Therapeutic Index of a P210(BCR-ABL)-specific Tyrosine Kinase Inhibitor: Activity on Lineage-committed and Primitive Chronic Myelogenous Leukemia Progenitors." Cancer Chemotherapy and Pharmacology 44, no. 5 (1999). https://doi.org/10.1007/s002800051001.

MLA (9th ed.) Citation

Kasper, Bernd, et al. "Favorable Therapeutic Index of a P210(BCR-ABL)-specific Tyrosine Kinase Inhibitor: Activity on Lineage-committed and Primitive Chronic Myelogenous Leukemia Progenitors." Cancer Chemotherapy and Pharmacology, vol. 44, no. 5, 1999, https://doi.org/10.1007/s002800051001.